financetom
Business
financetom
/
Business
/
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Nov 4, 2024 11:45 AM

Oct 31 (Reuters) - Independent advisers to the U.S. Food

and Drug Administration on Thursday voted against recommending

Lexicon Pharmaceuticals' ( LXRX ) add-on treatment to insulin

therapy for managing blood glucose levels in adults with type 1

diabetes and chronic kidney disease.

The panel voted 11 to 3 against recommending the drug,

chemically known as sotagliflozin.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved